CERETEC
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CERETEC (CERETEC).
Technetium-99m exametazime (Ceretec) is a lipophilic radiopharmaceutical that crosses the blood-brain barrier and is taken up by brain tissue in proportion to regional cerebral blood flow. Once inside cells, it undergoes intracellular conversion to a hydrophilic form, trapping it in the brain and allowing SPECT imaging.
| Metabolism | Not metabolized; undergoes intracellular conversion to a polar complex that is renally excreted. |
| Excretion | Renal: 40% unchanged; biliary/fecal: 60% (as metabolites and parent compound). |
| Half-life | Terminal: 6 hours (range 4–8 h); clinical: supports twice-daily dosing in nuclear medicine studies. |
| Protein binding | 92% bound to albumin. |
| Volume of Distribution | 2.5 L/kg; high due to extensive tissue distribution, particularly brain and liver. |
| Bioavailability | Oral: 5% (extensive first-pass metabolism); IV: 100%. |
| Onset of Action | IV: maximum brain uptake within 5 minutes; oral: N/A. |
| Duration of Action | IV: 2–6 hours for brain SPECT imaging; redistribution occurs over 24 hours. |
555-740 MBq (15-20 mCi) intravenously as a single dose for SPECT imaging.
| Dosage form | INJECTABLE |
| Renal impairment | No specific adjustment required; drug is eliminated primarily by hepatobiliary excretion. |
| Liver impairment | No specific guidelines; use caution in severe hepatic impairment. |
| Pediatric use | Body weight-based dose: 0.07-0.14 mCi/kg (2.6-5.2 MBq/kg), minimum 0.1 mCi, maximum 20 mCi. |
| Geriatric use | No specific adjustment; consider reduced renal and hepatic function in elderly. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for CERETEC (CERETEC).
| Breastfeeding | Not recommended during breastfeeding. If essential, pump and discard breast milk for at least 24 hours after administration to minimize infant exposure. M/P ratio unknown. |
| Teratogenic Risk | No adequate studies in pregnant women. Radiolabeled products emit ionizing radiation with potential fetal harm; risk is dose-dependent. Avoid in pregnancy unless benefit justifies risk. Use lowest possible dose. |
| Fetal Monitoring |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to exametazime or any component of the formulation"]
| Precautions | ["Use with caution in patients with hepatic or renal impairment","Risk of allergic reactions including anaphylaxis","Ensure adequate hydration to minimize radiation exposure to bladder"] |
| Food/Dietary | No known food interactions. Standard diet prior to imaging is acceptable. |
| Clinical Pearls | Ceretec (technetium-99m exametazime) is used in nuclear medicine for brain perfusion imaging. Administer within 30 minutes of reconstitution due to radiochemical instability. Ensure patient is not pregnant or breastfeeding. Patient should void immediately before imaging to reduce bladder radiation. No specific drug interactions but caution with drugs that alter cerebral blood flow. |
Loading safety data…
| Monitor fetal radiation exposure; consider cumulative radiation dose. No specific maternal monitoring required beyond standard radiopharmaceutical safety. |
| Fertility Effects | No known effects on fertility from technetium Tc 99m exametazime. Potential gonadal radiation exposure is minimal at diagnostic doses. |
| Patient Advice | This is a radioactive tracer used to image blood flow in your brain. · You will receive a small injection into a vein. · No special dietary restrictions before the test. · Drink plenty of water before and after the procedure to help eliminate the tracer. · You may need to empty your bladder right before imaging. · Inform your doctor if you are pregnant, breastfeeding, or have any allergies. |